Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $4.8 million.

  • Zentalis Pharmaceuticals' Share-based Compensation fell 5340.67% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.0 million, marking a year-over-year decrease of 165.31%. This contributed to the annual value of $67.3 million for FY2024, which is 2270.44% up from last year.
  • As of Q3 2025, Zentalis Pharmaceuticals' Share-based Compensation stood at $4.8 million, which was down 5340.67% from $6.3 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' Share-based Compensation's 5-year high stood at $31.4 million during Q4 2024, with a 5-year trough of $4.8 million in Q3 2025.
  • For the 4-year period, Zentalis Pharmaceuticals' Share-based Compensation averaged around $12.4 million, with its median value being $12.7 million (2024).
  • Per our database at Business Quant, Zentalis Pharmaceuticals' Share-based Compensation skyrocketed by 12595.82% in 2024 and then tumbled by 5340.67% in 2025.
  • Quarter analysis of 4 years shows Zentalis Pharmaceuticals' Share-based Compensation stood at $9.6 million in 2022, then surged by 44.4% to $13.9 million in 2023, then soared by 125.96% to $31.4 million in 2024, then tumbled by 84.61% to $4.8 million in 2025.
  • Its Share-based Compensation was $4.8 million in Q3 2025, compared to $6.3 million in Q2 2025 and $6.5 million in Q1 2025.